News
Issued by AGC Biologics, not Valneva SE
AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate
July 29, 2025 · View original source (Business Wire)
It isn’t one of Valneva SE’s news releases, so 6ix doesn’t show it on Valneva SE’s page or send it as an alert.